entertainment -WSS

entertainment

author：Wikipedia 2025-09-06 05:18:09 - browse：53

Sen. Bob Menendez (D-N.J.) Michael M. Santiago/Getty Images

WASHINGTON — With mounting calls for embattled Sen. Bob Menendez to resign, the pharmaceutical industry could see one of its historical, and increasingly rare, Democratic allies ousted from Congress.

The New Jersey senator is embroiled in another financial scandal after last week’s indictment over hundreds of thousands of dollars he and his wife allegedly accepted to influence military aid. The charges — which Menendez insists he will beat — come roughly seven years after he was accused of pressuring Medicare officials to resolve a dispute in favor of a lavish political donor. That case ended in a hung jury.

But this time around, Capitol lawmakers and New Jersey Democrats including Sen. Cory Booker, a longtime legislation partner, are calling on Menendez to resign. The mounting pressure and looming court battle spell out a hazy future for one of the pharmaceutical industry’s biggest allies in the Democratic Party.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Why the drug industry's warnings on the IRA's impact fall short

leisure time

hotspot

WSS

What happened to the House vote on health price transparency?

White House Covid adviser calls on docs to combat misinformation

Medicare threatens to cut off funding for HCA's Mission hospital

How digital tools helped lower hypertension in marginalized patients

Neurocrine congenital adrenal hyperplasia trial succeeds

Free Covid tests will again be offered to all U.S. households

knowledge

entertainment

hotspot

Duchenne breakthrough therapy leaves behind pioneering families

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Apple is now the first public company to be valued at $3 trillion

A disappointing year of Humira biosimilars

The high cost of giving birth even with insurance

House panel takes first step toward fixing drug shortages

As demand for Covid shots wanes, Moderna seeks its next success

FDA weighs limits of animal data in assessing artificial wombs

Walensky prepares to leave CDC — and Congress — behind

What should King Charles tell the public about his cancer?

leisure time

Neurocrine congenital adrenal hyperplasia trial succeeds

People with substance use disorder deserve online privacy

What happened to the House vote on health price transparency?

Why did Pfizer dish out millions for a Super Bowl ad?

Covid’s new normal has set in amid another rise in cases

White House Covid adviser calls on docs to combat misinformation

knowledge

leisure time

hotspot

explore